Thank you, Madam Chair.
Madam Chair, I would like to thank all the presenters here.
My question will go to Mr. Lipkus of IPIC.
It has been indicated that concentrating on the TRIPS waiver as a magic bullet for vaccine access and production will not work. First, am I right in saying that the TRIPS member countries must be pragmatic and realistic, and agree on what are truly effective solutions first based on, as you said, flexibility?
Second, seeing that we need to seek an agreement with other member countries on these broader considerations first, am I right in saying that this would be your recommendation?